Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
Rhea-AI Summary
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) has announced the departure of Matthew Shaulis, Chief Commercial Officer and US President, effective late September 2024. The Commercial Leadership team will now report directly to Søren Tulstrup, President and CEO, while a search for a new CCO and US President is underway.
Shaulis expressed pride in the company's progress and its commitment to developing transformative products for patients with rare immunological diseases. Tulstrup acknowledged Shaulis's significant contributions, including commercialization efforts in Europe, acceleration of the ConfIdeS US pivotal study, and initiation of US launch planning.
Positive
- Smooth transition with Commercial Leadership team reporting directly to CEO
- Ongoing search for new CCO and US President indicates proactive management
Negative
- Departure of key executive (CCO and US President) may disrupt commercial operations
- Potential loss of expertise and leadership in US market expansion efforts
Matthew Shaulis, CCO and US President, Hansa Biopharma said, "Joining Hansa was a key moment for my career and while the decision to leave was hard, especially given the company's solid progress, I know that the company will continue to advance innovative science, deliver on its commitment to develop and launch transformative new products, and help patients with rare immunological diseases. I'm proud of the work we have done together at Hansa."
Søren Tulstrup, President and CEO, Hansa Biopharma remarked, "Matt has been a fantastic addition to the Hansa executive team and has made significant contributions across the organization over the past years. I want to thank Matt for his commitment and dedication to advancing key priorities including commercialization efforts in
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
https://mb.cision.com/Public/1219/4028110/bc9b46375205ee0e.pdf | 20240822 Shaulis Departure en |
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-announces-departure-of-chief-commercial-officer-matthew-shaulis-302229646.html
SOURCE Hansa Biopharma AB
FAQ
When is Matthew Shaulis leaving Hansa Biopharma (HNSA)?
Who will the Commercial Leadership team report to after Shaulis's departure from Hansa Biopharma (HNSA)?
What key contributions did Matthew Shaulis make during his tenure at Hansa Biopharma (HNSA)?
Is Hansa Biopharma (HNSA) seeking a replacement for Matthew Shaulis?
